The National Institute for Health and Care Excellence has released new draft guidelines calling for faster treatment of patients with kidney stones experiencing severe pain.
News
Record numbers taking part in life sciences industry research
The number of people taking part in NHS clinical research studies sponsored by the life sciences industry has risen dramatically over the last year, show new figures by the National Institute for Health Research (NIHR).
US approves Janssen’s HIV pill Symtuza
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
MPs vote for UK to remain part of EMA
MPs have voted 305-301 that the UK should negotiate to remain part of the European Medicines Agency following Brexit.
Vertex mulls over NHS England’s offer for CF drugs
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.
Roche’s antiviral hits flu targets in PhIII trial
Roche says its investigational flu drug baloxavir marboxil, in-licensed from Japan’s Shionogi, has met key goals in a late-stage trial.
Pfizer kicks off PhIII programme for haemophilia B gene therapy
Pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B.
UK panel says human embryo editing ‘morally permissible’
An independent ethics panel in the UK has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”.
NICE issues cerebral palsy guideline for adults
The National Institute for Health and Care Excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy.
EU approval for Akcea/Ionis’ rare disease therapy
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Enter now and showcase your talents industry-wide
The all new Sales Awards offers a unique opportunity for sales professionals at all levels of their career to sharpen their skills and showcase their talents industry-wide.
With just 6 weeks to go spaces are filling up fast – reserve your place now to avoid missing out
The PharmaTimes Marketer of the Year competition offers a unique opportunity for all marketers, from aspiring to experienced, to sharpen their skills and showcase their talents against marketing professionals, industry-wide.
Sobi launches Kineret for AOSD, SJIA
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
NICE backs AZ’ asthma biologic Fasenra
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
FDA approves first smallpox therapy
US regulators have approved the first treatment designed to mitigate the impact of a potential outbreak of smallpox caused by bioterrorism.
